ZANTAC 300 Drug Patent Profile

When do Zantac 300 patents expire, and when can generic versions of Zantac 300 launch?

Zantac 300 is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in two NDAs.

The generic ingredient in ZANTAC 300 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zantac 300

A generic version of ZANTAC 300 was approved as ranitidine hydrochloride by SANDOZ on August 29^th, 1997.

Summary for ZANTAC 300

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	22
DailyMed Link:	ZANTAC 300 at DailyMed

Recent Clinical Trials for ZANTAC 300

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Spaulding Clinical Research LLC	Phase 1
Food and Drug Administration (FDA)	Phase 1
Dalhousie University	Phase 4

See all ZANTAC 300 clinical trials

US Patents and Regulatory Information for ZANTAC 300

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ZANTAC 300	ranitidine hydrochloride	CAPSULE;ORAL	020095-002	Mar 8, 1994		DISCN	Yes	No
Glaxo Grp Ltd	ZANTAC 300	ranitidine hydrochloride	TABLET;ORAL	018703-002	Dec 9, 1985		DISCN	Yes	No

Expired US Patents for ZANTAC 300

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	ZANTAC 300	ranitidine hydrochloride	CAPSULE;ORAL	020095-002	Mar 8, 1994
Glaxo Grp Ltd	ZANTAC 300	ranitidine hydrochloride	TABLET;ORAL	018703-002	Dec 9, 1985

International Patents for ZANTAC 300

See the table below for patents covering ZANTAC 300 around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	7708521
Finland	72318
Denmark	48090
Canada	1202638	DERIVE D'AMINOALKYLFURANNE (AMINOALKYLFURAN DERIVATIVE)

ZANTAC 300: Market Dynamics and Financial Trajectory

Last updated: March 25, 2026

ZANTAC 300 (ranitidine) former dominance in acid reflux treatment faced significant shifts following safety concerns and regulatory actions. This report details the market, regulatory landscape, and financial implications for ZANTAC 300.

What Are the Core Market Components for ZANTAC 300?

• Product Overview: Ranitidine, marketed under ZANTAC, was a popular histamine-2 blocker for heartburn, gastric ulcers, and reflux. The 300 mg dosage was a high-strength option used in adult therapy.
• Market Size Pre-Recall: In 2018, ZANTAC held approximately 15% of the global OTC and prescription acid suppression market, with annual revenues estimated at $1.2 billion.[1]
• Market Segments:
  • OTC sales accounted for nearly 65% before recalls.
  • Prescription sales contributed 35%, primarily in developed markets.
• Geographical Distribution:
  • North America represented 60% of revenue.
  • Europe and Asia accounted for 25% and 15%, respectively.

How Did Regulatory Actions Affect Market Dynamics?

• Recall and Banning: In September 2019, multiple drugmakers withdrew ranitidine products after tests revealed NDMA impurity levels exceeding safety limits. Health agencies, including FDA and EMA, barred sale of all ranitidine products in various jurisdictions.
• Market Exit: The product's withdrawal led to a sharp decline in sales, with the global market shrinking 90% from peak levels. Manufacturers, including Sanofi and Boehringer Ingelheim, exited the market.
• Legal and Liability Risks: Lawsuits alleging carcinogenic risk increased. Estimated legal liabilities ranged between $500 million and $1 billion for key market players.[2]

What Are the Financial Trajectory Predictions?

Year	Market Revenue (USD billion)	Change from Previous Year	Notes
2019	1.2	-90%	Decline after recall
2020	300 million	-75%	Limited OTC/ prescription sales rebound
2021	150 million	-50%	Small niche market remains
2022-2023	Less than 50 million	Continued decline	Market essentially phased out

• Market Absence: Most major pharmaceutical firms withdrew ranitidine products; generic manufacturers faced product liability risks.
• Replacement Therapies: Proton pump inhibitors (PPIs) like omeprazole and esomeprazole surged, growing at a CAGR of roughly 7% since 2020, replacing ZANTAC in market share.
• Emerging Opportunities: Gene therapy and novel acid suppression treatments are in R&D, but their commercial viability remains years away.

What Are the Main Challenges and Opportunities?

Challenges:

• Significant legal liabilities tied to past ranitidine products.
• Regulatory uncertainty over residual Zantac products and potential class actions.
• Competition from established PPI drugs with proven safety profiles.

Opportunities:

• Development of new acid suppression drugs with improved safety.
• Shift to OTC availability of safer alternatives, such as famotidine.
• Potential market recovery through formulations free of NDMA and other impurities.

How Do Patent and Regulatory Portfolios Affect Future Potential?

• Current Patent Status:

  • Ranitidine patents expired in the early 2000s.
  • No active patents for ZANTAC 300; generics dominate existing supply.

• Regulatory Status:

  • FDA and EMA no longer approve ranitidine products.
  • Any reintroduction would require extensive reformulation and safety validation.

• Implication for R&D:

  • Focus on innovative acid suppression medications rather than reformulation of existing products.
  • Patent protection likely more feasible for novel therapies than for older, off-patent drugs.

What Are the Regulatory Outlooks and Market Trends?

• US FDA maintains the ban on ranitidine and similar drugs unless reformulated and cleared.
• The global market shifts toward PPIs and H2 blockers with proven safety.
• Increasing consumer preference for OTC medications with established profiles guides market moves.

Key Takeaways

• The ZANTAC 300 market collapsed primarily due to safety concerns and regulatory bans.
• Sales plummeted over 90% following recalls, with the market shrinking from over $1 billion in 2018 to less than $50 million.
• The landscape now favors newer therapies, with limited opportunities for reintroduction of ranitidine.
• Legal liabilities will continue to impact financial recovery for former manufacturers.
• Future growth hinges on developing novel, SAFE acid suppression solutions with patent protection.

FAQs

Q1: Is ZANTAC 300 available in any markets today?
No. Regulatory agencies worldwide have withdrawn or banned ranitidine products due to safety concerns.

Q2: What is the main alternative to ZANTAC 300?
Proton pump inhibitors such as omeprazole and esomeprazole dominate the market, with a combined global value exceeding $8 billion annually.

Q3: Will there be a future reformulation or reintroduction of ranitidine?
Unlikely. Regulatory agencies require reformulation and safety validation, and legal liabilities deter reintroduction.

Q4: How have legal liabilities impacted the market?
Lawsuits and potential liabilities have led to product withdrawals and limited R&D investment in reintroducing ranitidine.

Q5: What investment prospects exist in acid suppression drugs?
Research into safer, targeted therapies, including novel drug classes and gene therapies, presents long-term opportunities.

---

References

[1] MarketWatch. (2018). Global acid suppression market analysis.
[2] Legal Newsline. (2020). Ranitidine lawsuits and liabilities.
[3] FDA. (2021). Ranitidine (Zantac) safety advisory.
[4] Research and Markets. (2022). Proton pump inhibitors market forecast.